Regeneron Pharmaceuticals Inc (NASDAQ: REGN) crashed more than 15% this morning on disappointing data from Phase 3 trials of its experimental drug itepekimab.Itepekimab is a drug candidate for chronic obstructive pulmonary disease (COPD) that the biotech firm developed with Paris headquartered Sanofi.Including today’s plummet, REGN shares are down nearly 35%…
German automaker Volkswagen said the company is planning to increase investments in the US to reduce the impact of…
Trump administration has reportedly picked Palantir Technologies Inc. (NASDAQ: PLTR) as its primary data analysis partners. Shares of the…
Sunrun Inc (NASDAQ: RUN) has been a major disappointment for investors in recent weeks, but a senior analyst at…
German stocks have been on a tear in 2025, vastly outperforming both their European peers and U.S. counterparts.The DAX…
Intel has announced plans to lower its global headcount by more than 20% under the leadership of Lip-Bu Tan,…
Gap Inc (NYSE: GAP) shares plunged some 20% on Friday, rattled by concerns over tariffs and their potential impact…
U.S. equities may be poised for a significant rally in the second half of 2025, according to Chris Harvey,…
Bitcoin remains stuck below $110,000 as the financial landscape maintains a cautious tone following the latest Fed updates.While most…